Disruption of splicing-regulatory elements using CRISPR/Cas9 to rescue spinal muscular atrophy in human iPSCs and mice. Issue 1 (3rd September 2019)

• Record Type: Journal Article
• Authors: Li, Jin-Jing; Lin, Xiang; Tang, Cheng; Lu, Ying-Qian; Hu, Xinde; Zuo, Erwei; Li, He; Ying, Wenqin; Sun, Yidi; Lai, Lu-Lu; Chen, Hai-Zhu; Guo, Xin-Xin; Zhang, Qi-Jie; Wu, Shuang; Zhou, Changyang; Shen, Xiaowen; Wang, Qifang; Lin, Min-Ting; Ma, Li-Xiang; Wang, Ning; Krainer, Adrian R; Shi, Linyu; Yang, Hui; Chen, Wan-Jin
• Is Part Of: National science review. Volume 7:Issue 1(2020)
• Page Start: 92
• Page End: 101
• Publication Date: 2019-09-03
• Subjects: spinal muscular atrophy -- SMN2 -- splicing-regulatory elements -- CRISPR/Cas9 -- germline correction; Science -- Periodicals; 505
• DOI: 10.1093/nsr/nwz131
• Languages: English
• ISSNs: 2095-5138

Abstract

Abstract: We here report a genome-editing strategy to correct spinal muscular atrophy (SMA). Rather than directly targeting the pathogenic exonic mutations, our strategy employed Cas9 and guide-sgRNA for the targeted disruption of intronic splicing-regulatory elements. We disrupted intronic splicing silencers (ISSs, including ISS-N1 and ISS + 100) of survival motor neuron (SMN) 2, a key modifier gene of SMA, to enhance exon 7 inclusion and full-length SMN expression in SMA iPSCs. Survival of splicing-corrected iPSC-derived motor neurons was rescued with SMN restoration. Furthermore, co-injection of Cas9 mRNA from Streptococcus pyogenes (SpCas9) or Cas9 from Staphylococcus aureus (SaCas9) alongside their corresponding sgRNAs targeting ISS-N1 into zygotes rescued 56% and 100% of severe SMA transgenic mice ( Smn −/−, SMN2 tg/− ). The median survival of the resulting mice was extended to >400 days. Collectively, our study provides proof-of-principle for a new strategy to therapeutically intervene in SMA and other RNA-splicing-related diseases.